Abstract Purpose:The methylation status of hMLH1, CDKN2A, and MGMT was investigated in a panel of synchronous cancers of the ovary and endometrium, fulfilling the clinicopathologic criteria for independent primary tumors to define the possible role of epigenetic mechanisms in the development of these cancers. Experimental Design: Bisulfite-converted DNA from 31tumors (13 endometrial and 18 ovarian carcinomas) and from matched normal tissue of 13 patients was analyzed by a methylationspecific PCR assay at the CpG-rich 5 ¶ regions of all three genes. In all tumors, we also investigated the presence of microsatellite instability and hMLH1immunohistochemical expression in relation to hMLH1 hypermethylation status. Results: Methylation of hMLH1, CDKN2A, and MGMT was detected in 39%, 41%, and 48% of endometrial and ovarian tumors, respectively. hMLH1 hypermethylation was observed in all tumors of five patients, and it was invariably associated with loss of hMLH1protein and presence of microsatellite instability. CDKN2A and MGMT methylation was randomly detected among both endometrial (45% and 24% of cases, respectively) and ovarian carcinomas (39% and 39% of cases, respectively). Concordant methylation at two or three genes was observed in 35% of cases. Conclusions: Epigenetic inactivation of hMLH1, CDKN2A, and MGMT may be a common and early event in the development of synchronous primary endometrial and ovarian carcinomas and may qualify as a marker of a field cancerization encompassing the ovary and endometrium. Detection of MGMT hypermethylation may be useful to define a set of gynecologic malignancies with a specific sensitivity to alkylating chemotherapy.
The simultaneous development of primary carcinomas at different sites in the female genital tract is a well-known event (1 -3) . Although the etiology and pathogenesis of this phenomenon are unclear, it has been postulated that embriologically similar tissues, when simultaneously subjected to hormonal influences or to carcinogen(s), may develop synchronous neoplasms within a single preneoplastic field (4) . Synchronous primary ovarian and endometrial carcinomas are the most frequently documented in this tract (5) , and several lines of evidence support the existence of a field cancerization encompassing the ovary and the endometrium. First, the incidence of these tumors has been reported to be 2 to 10 times higher than that expected based on the incidence of each cancer alone (6) . Recently, a large Swedish study using the nationwide Family Cancer Database reported a strong clustering of endometrial and ovarian carcinomas, especially in cases showing endometrioid histology of the ovarian cancer (7) . Intriguingly, this histologic type is relatively rare among ovarian carcinomas, and it has been reported to be associated with the same risk factors as endometrioid carcinomas of the endometrium (8) . Second, there is uniform agreement that synchronous primary cancers of the ovary and the endometrium should be regarded as a quite different prognostic entity than single advanced-stage cancer of either site. Indeed, most of these patients have early-stage and low-grade cancers in both organs and have an overall prognosis that is surprisingly better than that resulting from the classification of their disease as a single organ carcinoma with metastasis. Furthermore, several histopathologic studies have indicated a very high percentage of endometrioid or clear cell histotypes among these tumors, often concordant in both sites (2, 5, 9, 10) . Third, there is a strong relationship between endometrioid or clear cell ovarian carcinomas and endometriosis, a common gynecologic condition in which normal-appearing endometrial tissue proliferates ectopically, outside the uterine cavity. To date, many epidemiologic, histologic, and molecular data indicate the malignant precursor role of endometriosis in the development of these tumors (11, 12) ; furthermore, ovarian endometriosis has been reported in around 30% of patients with synchronous primary cancers of the ovary and endometrium (5) .
In the last two decades, the main challenge regarding coexisting carcinomas of the ovary and endometrium has been to make a differential diagnosis between metastatic disease and independent primaries because there will be quite different clinical implications and prognosis in each case. Thus far, this discrimination has largely relied on the conventional clinicopathologic criteria proposed by Ulbright and Roth (3) and more recently revised by Scully et al. (13) . On the contrary, immunohistochemistry, DNA flow cytometry (14) , and clonality analyses using molecular pathology techniques have been employed with very limited efficacy in cases showing inconclusive clinicopathologic features (15, 16) . Surprisingly, in some cases, the tumor molecular profiles led to the opposite conclusion of the clinicopathologic diagnosis, by showing either identical genetic patterns in cases fulfilling the clinicopathologic criteria for independent primary tumors (17, 18) or different profiles in metastatic carcinomas (18) .
In this work, we selected a panel of synchronous ovarian and endometrial carcinomas fulfilling the clinicopathologic criteria for independent primary tumors and investigated whether de novo promoter methylation may be a frequent genetic marker of these tumors, as already shown for endometrial carcinomas of endometrioid histologic type (19) . Moreover, we evaluated the frequency of identical molecular profiles in tumors from the same patient to consider the hypothesis that a preneoplastic field may really be a common event underlying the pathogenesis of these tumors.
Materials and Methods
Patients and samples. Thirteen cases of synchronous carcinomas of the uterine corpus and ovary were retrieved with informed consent from Surgical Pathology files at the Varese hospital. These cases had been collected during a 29-year period ranging from 1976 to 2005. The series consisted of 31 neoplasms, including 13 endometrial and 18 ovarian carcinomas (five patients showed bilateral ovarian neoplasia), simultaneously detected during surgery. In all cases, a total abdominal hysterectomy and bilateral salpingoophorectomy had been done. The use and the type of adjuvant therapy showed a great heterogeneity because our series had been collected during a 29-year period. Clinical information, therapy, and patient follow-up data were obtained from the hospital charts, the tumor registry of the province of Varese, and from communication with gynecologic oncologists. The cases were classified as synchronous carcinomas based on conventional clinicopathologic findings and patient follow-up according to the criteria proposed by Eifel et al. (2) , Ulbright and Roth (3), Prat et al. (14) , and Scully and Clement (13) . The histopathologic study included a complete revision of all cases done separately by two senior pathologists. The following variables were evaluated: histologic type, grade, stage, size, the presence/extent of blood vessels, tubal and miometrial invasion, bilaterality and pattern of ovarian involvement, and coexistence with endometriosis or endometrial hyperplasia. The immunoperoxidase study was done on formalin-fixed paraffin sections that were dewaxed and rehydrated using Bio-Clear (Bio-Optica, Milan, Italy) and alcohol.
Endogenous peroxidase was blocked by dipping sections in 3% aqueous H 2 O 2 for 10 minutes, and antigen retrieval was done with a 10-minute microwave treatment in 10 mmol/L citrate buffer (pH 6). The immunostaining was done with the avidin-biotin peroxidase complex technique (20) using diaminobenzidine as chromogen. Sections were incubated overnight at 4jC with a mouse monoclonal antibody against full-length hMLH1 protein (G168-15, PharMingen, San Diego, CA) at 1:100 dilution. Sections were lightly counterstained with hematoxylin. The normal staining pattern for hMLH1 is nuclear, and a case was considered positive only in the presence of nuclear staining of neoplastic cells. A case was considered negative for expression of hMLH1 only when there was a complete absence of nuclear staining of neoplastic cells in the presence of an unquestionable internal positive control represented by normal epithelial, stromal and muscle cells, or lymphocytes.
DNA extraction and methylation-specific PCR. Genomic DNA was extracted from representative 8-Am sections of each endometrial and ovarian carcinoma and from matched normal lymph nodes of all the patients included in this study. Three sections of every specimen were cut from paraffin-embedded tissue, treated twice with xylene, and then washed twice with ethanol. DNA was extracted using a Dneasy Tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Neoplastic areas were manually microdissected for DNA extraction and contained at least 70% of tumor cells, to minimize contamination by normal cells (21) .
Methylation-specific PCR was carried out following the original method developed by Herman et al. (22) with the protocol modifications reported by Boyd and Zon (23) to improve DNA recovery after bisulfite treatment. Briefly, 300 to 600 ng of genomic DNA were subjected to sodium bisulfite treatment, then purified using Microcon 100 cartridges (Millipore, Billerica, MA), and stored at À20jC. The methylation analysis was assessed for the CpG-rich 5 ¶ regions of three genes (i.e., hMLH1, CDKN2A, and MGMT). These genes were selected because of their high frequency of promoter hypermethylation in cancers with a methylator phenotype of the colonrectum and endometrium (19, 24, 25) . Bisulfite-converted DNA was amplified separately using the published methylation-specific PCR primers specific for methylated and unmethylated sequences of hMLH1, CDKN2A, and MGMT CpG sites (22, 24, 26) . Forward primers were synthesized with a fluorescent tag (FAM or HEX) on the 5 ¶end and purified using standard high-performance liquid chromatography. A single round of fluorescent PCR was done using 5 AL of the bisulfiteconverted DNA (30-60 ng assuming 100% yield) in a 15-AL reaction containing 1.5 AL of 10Â buffer (Roche, Mannheim, Germany), 0.3 Amol/L primer pairs, 200 Amol/L deoxynucleotide triphosphates, and 2 units DNA polymerase (Roche). Annealing temperatures and MgCl 2 buffer concentrations optimized for each primer mix are reported in Table 1 together with the specific size and the fluorescent tag of each amplicon. Thermal cycling conditions were 5 minutes at 95jC, 10 cycles of 94jC/50 seconds, specific T annealing/50 seconds, and 72jC/50 seconds and 25 cycles of 89jC/30 seconds, specific T annealing/30 seconds, and 72jC/30 seconds. All PCRs were done with positive controls for both unmethylated and methylated alleles and no DNA control. DNA from normal lymphocytes treated in vitro with SssI methyltransferase (New England Biolabs, Ipswich, MA) was used as a positive control for methylated alleles, whereas the same DNA without any enzymatic treatment served as a positive control for unmethylated alleles. The fluorescently labeled PCR products were electrophoresed on an Applied Biosystems 310 automated DNA sequencer (Applied Biosystems, Milan, Italy), and the fluorescent signals from the differently sized alleles were recorded and analyzed using Genescan software (version 2.1; Applied Biosystems). All methylation-specific PCR data have been obtained from at least two independent modifications of DNA, and we scored as positive only signals detectable in repeated experiments.
Microsatellite analysis. Microsatellite status was assessed by a fluorescent pentaplex PCR of five quasi-monomorphic mononucleotide (27) . Once again, the fluorescently labeled PCR products were electrophoresed on an Applied Biosystems 310 automated DNA sequencer (Applied Biosystems). According to the criteria reported by Suraweera et al. (27) , a tumor was classified as high-frequency microsatellite instability when allelic size variations were observed in z3 of 5 markers, whereas it was defined as microsatellite stable when allelic size variations were observed in V2 of 5 markers.
Statistical analysis. Statistical analysis was assessed using Fisher's exact test and m 2 test with Yates' correction (SPSS 7.5 software).
Results
Clinicopathologic profile of the tumors. The main clinicopathologic features and details of therapy of coexisting endometrial and ovarian tumors are reported in Table 2 . The ages of patients at diagnosis ranged from 40 to 76 years, with a median age of 58 years. Endometrial tumors showed sizes ranging from 0.5 to 7 cm (median size, 3.4 cm). In 12 of 13 cases (92.3%), they showed an endometrioid histologic type; two cases were associated with a mucinous component; 10 of 12 cases were well-differentiated (G1) neoplasms. One case displayed a clear cell histologic type. Foci of atypical hyperplasia were observed near the carcinoma in two patients (cases 5 and 10).
Ovarian tumors showed bilaterality in 5 of 13 cases (38.4%). The ovarian tumor diameter ranged from 1.5 to 25 cm, with a median diameter of 8.6 cm. The majority of ovarian tumors were solid-cystic masses (13 of 18, 72.2%); whereas in five cases (27.8%), solid neoplasms were observed. Residual foci of ovarian endometriosis were identified in only one case (case 7). In 13 of 18 (72.2%) ovarian tumors, an exclusive (12 cases) or predominant (one case showing focal mucinous differentiation) endometrioid histologic type was present. Two mucinous, two serous papillary neoplasms, and one clear cell carcinoma were observed. The majority of ovarian tumors were well differentiated (G1; 9 of 18, 50%) or moderately differentiated (G2; 7 of 18, 38.8%) neoplasms. Only two patients (11.2%) showed poorly differentiated (G3) ovarian tumors. Ten patients had ovarian tumors limited to the ovary or ovaries (76.9%; International Federation of Gynaecology and Obstetrics stage I). An extraovarian lesion was present in one case (International Federation of Gynaecology and Obstetrics stage II, case 1 in Table 2 ), and extrapelvic spreading was observed in two cases showing a serous papillary ovarian carcinoma (International Federation of Gynaecology and Obstetrics stage III, cases 2 and 10 in Table 2 ). After surgery, 11 patients underwent adjuvant chemotherapy: four patients received four to six cycles of combined chemotherapy with platinum-derived compound, antracyclins (Adriamycin or epirubicin), and cyclophoshamide; five patients received six cycles of platinum-derived compounds (carboplatinum or cisplatinum), and paclitaxel was administrated in two cases; four patients underwent external pelvic radiotherapy, in association with a vaginal brachitherapy in two of them. Follow-up data were collected for a mean period of 115 months (range, 6-314 months). Nine patients (69.5%) are alive without evidence of disease. One patient (case 3) died of an unrelated cause after 54 months, without evidence of recurrence of neoplastic disease. Three patients died of disease (23%) after 7, 36, and 43 months, respectively.
Synchronous neoplasms showed an identical histologic type in nine cases, including eight endometrioid carcinomas and one clear cell carcinoma. On the contrary, the histologic type was discordant in four cases comprising two endometrioid carcinomas of the endometrium associated with ovarian mucinous carcinomas and two endometrioid carcinomas of the endometrium associated with ovarian serous papillary carcinomas.
De novo promoter hypermethylation and microsatellite instability in synchronous endometrial and ovarian tumors. Methyhylation of hMLH1, CDKN2A, and MGMT was detected in 39%, 41%, and 48% of endometrial and ovarian tumors, respectively. No PCR product using methylation-specific primers was observed for normal DNA from lymph nodes of each patient. Overall, at least one methylated gene was observed in tumors of 12 of 13 (92%) patients for a total of 24 of 31 (77%) carcinomas included in this study. A diagram of the neoplasm arrangement based on the number of methylated loci per tumor of each patient is shown in Fig. 1 . Methylation of hMLH1 was observed in all synchronous tumors of five patients (five endometrial and seven ovarian carcinomas), whereas CDKN2A and MGMT methylation was randomly detected among both endometrial (45% and 24% of the cases, respectively) and ovarian carcinomas (39% and 39% of the cases, respectively). Moreover, concordant methylation at two or three genes was observed in 35% of cases. In all 12 tumors with hMLH1 methylation, we always identified the loss of the immunohistochemical expression of the protein and the presence of a high-frequency microsatellite instability phenotype. Figure 2 shows an example of this tumor phenotype observed for all the three synchronous carcinomas of patient 4. By contrast, all tumors without hMLH1 methylation exhibited intense hMLH1 expression and an absence of microsatellite instability in all the five monucleotide markers analyzed (Fig. 3) .
Using the pentaplex PCR for microsatellite analysis, four tumors (three endometrial and one ovarian carcinomas) showed deletions in all markers with an average size of allelic shifts of 7 F 1.5. The remaining eight high-frequency microsatellite instability tumors showed deletions in at least three mononucleotides with an average size of shortenings of 4 F 1.6. Variable patterns of microsatellite instability were found among tumors of the same patient, when considering the number of microsatellite instability -positive markers and/or the size of the deletions (Fig. 3) .
No association between clinicopathologic features (tumor size, histotype, grade, bilaterality of ovarian involvement, stage, and follow-up) and CpG island methylation or high-frequency microsatellite instability phenotype was observed.
Discussion
During the last two decades, many epidemiologic and clinicopathologic data have shown that women with synchronous primary tumors of the endometrium and ovary represent a distinct subgroup of patients with early-stage and low-grade cancers in both organs and an overall prognosis surprisingly better than if their disease were classified as a single organ carcinoma with metastasis (2, 5, 9, 28) . Although the pathogenesis of these tumors is completely unknown, there are several lines of evidence which suggest that these tumors may share both the etiologic and histopathologic features of estrogen-dependent neoplasms of the endometrium (10, 29, 30) . For the first time, this work has shown a high frequency of de novo hMLH1, CDKN2A, and MGMT promoter methylation in a panel of 31 synchronous ovarian and endometrial carcinomas, fulfilling the clinicopathologic criteria for independent primary tumors.
Considering the methylation status of each gene separately, 39% of tumors (5 of 13 endometrial carcinomas and 7 of 18 ovarian carcinomas) showed hMLH1 promoter hypermethylation invariably associated with the absence of immunohistochemical expression of the protein and a microsatellite Fig. 1 . De novo methylation and microsatellite instability (MSI) phenotype in synchronous endometrial and ovarian carcinomas. n, high-frequency microsatellite unstable tumors; , presence of promoter hypermethylation; 5, microsatellite stable tumors or absence of promoter hypermethylation; À, not available. E, endometrium; Lt, left ovary; Rt, right ovary. Fig. 2 . Coexistence of hMLH1promoter methylation, loss of hMLH1immunohistochemical expression, and microsatellite instability in the endometrial and both the ovarian carcinomas of the same patient (case 3 inTable 1). hMLH1 MET, specific primers for hMLH1-methylated sequences; hMLH1 UNMET, specific primers for hMLH1-unmethylated sequences.
instability phenotype. This frequency of microsatellite instability is almost double that reported for singly occurring sporadic endometrioid carcinomas of both the endometrium (19, 31 -33) and ovary (34) . On the contrary, it is consistent with the frequency of hMLH1 hypermethylation and/or microsatellite instability percentage recently observed by two different groups analyzing the synchronous ovarian and endometrial carcinomas of a total of 29 patients (35, 36) . To date, only one study has reported a very low incidence of microsatellite instability in a series of 45 patients with synchronous ovarian and endometrial carcinomas (37) . This discrepancy may be explained by the fact that these authors did microsatellite instability analysis using conventional methods involving polyacrylamide gel and autoradiography, whereas our study and the studies by Kaneki et al. (35) and Irving et al. (36) used a high-resolution method involving fluorescence-labeled PCR and laser scanning. This is a critical point especially taking into account the small shortenings usually observed in mononucleotide markers when microsatellite instability is present in endometrial cancers (27) . Second, almost 40% of the ovarian carcinomas analyzed by Shannon et al. were unusually non endometrioid tumors in contrast with those examined in our study and in the studies of Kaneki et al. (35) and Irving et al. (36) .
Overall, these data suggest that epigenetic silencing of hMLH1 may play a more significant role in synchronous than in singly occurring carcinomas of the endometrium and ovary, especially when endometrioid histology is present at both sites. In addition, because it has been shown that hMLH1 hypermethylation is an early event in human endometrial tumorigenesis, being present in 10% of typical and in 33% of atypical endometrial hyperplasia (38) , as well as being involved in the malignant transformation of endometriosis (11) , it is reasonable to infer that abnormal methylation of hMLH1 may be an early indicator of tumorigenesis for a large fraction of synchronous ovarian and endometrial carcinomas. In this respect, further investigations of hMLH1 hypermethylation status in normal-appearing cells and preneoplastic lesions adjacent to neoplastic tissues of these tumors could be useful.
Besides microsatellite instability and hMLH1 hypermethylation, synchronous endometrial and ovarian carcinomas often exhibit other genetic alterations known to be early events in the development of endometrioid carcinoma of the endometrium, such as PTEN, b-catenin/CTNNB1, and K-ras abnormalities (36, 39) . Until now, mutation tests for these genes as well as microsatellite instability analysis were mainly employed in these tumors to support a differential clinicopathologic diagnosis between metastatic disease and independent primaries. Surprisingly, many discrepancies between the two approaches were observed. In particular, most cases fulfilling the clinicopathologic criteria for independent primaries were found to exhibit identical gene mutations or similar microsatellite instability patterns in both endometrial and ovarian carcinomas (36, 40) . In agreement with these findings, our study showed that when hMLH1 hypermethylation was observed in one of the synchronous primary cancers the other cancers of the same patient also exhibited hypermethylation of the gene, accompanied by the loss of the immunohistochemical expression of the protein and the presence of a microsatellite instability phenotype (Figs. 1 and 2 ). As already suggested by other investigators, one explanation for these results may be the hypothesis of the existence of a field effect in the upper genital tract and the ovaries. As in other sites, a field cancerization phenotype could be the result of either independent molecular events affecting multiple cells separately under the action of a common carcinogenic agent, or one molecular event in a single clonal progenitor that gives rise to multiple foci of tumorigenesis via mechanisms of widespread clonal expansion (41) . In this connection, many histologic, epidemiologic, and molecular observations directly support the hypothesis that endometrioid and clear cell ovarian carcinomas may arise through malignant transformation of multiple foci of atypical endometriosis (12) . Although the molecular basis of a field defect remains elusive, accumulating evidence suggests that aberrant methylation of promoter associated CpG islands seem to be early events in tumorigenesis (42) and may mark the field defect that precedes and predisposes to the development of cancer (43) . Very recently, Shen et al. (44) showed that MGMT methylation could be one of the mediators of field cancerization in the colon mucosa, being present not only in 46% of the colorectal cancers examined but also in over 70% of normal-appearing mucosal specimens that were located 1 and 10 cm away from the tumors with MGMT methylation. In this connection, a new and interesting result of our work concerns the unexpectedly high frequency of MGMT and CDKN2A hypermethylation, observed in 48% and 41% of tumors, respectively. This finding supports the hypothesis that the epigenetic inactivation of specific genes is a common and early event in the development of synchronous primary endometrial and ovarian tumors and may qualify as a marker of a field defect in these tumors.
CDKN2A is one of the cycle-dependent kinase inhibitors and acts as a negative cell cycle regulator (45) . It is thought to be a potent tumor suppressor gene because of its negative effect on the cell cycle; indeed, frequent mutations, deletions, or promoter hypermethylation were shown in a variety of human tumors (46) . In agreement with our data, Tsuda et al. (47) suggested that promoter hypermethylation of CDKN2A is a very common event in endometrial tumorigenesis, causing loss of p16 protein in 50% of endometrioid endometrial carcinomas and 44% of endometrial hyperplasia. Analogously, Katsaros et al. (48) found CDKN2A promoter methylation in 40% of epithelial ovarian cancers analyzing a wide series well representative of all histologic types. Other groups have reported a lower rate of CDKN2A methylation in singly occurring ovarian and endometrial carcinomas (19, 49 -52) as well as in atypical endometriosis (11) . The reason for this discrepancy might partly rest on the series of tumors analyzed, often small or heterogeneous for the histologic type. Our findings clearly show that the silencing of this gene is a frequent feature of synchronous primary endometrial and ovarian tumors and may be used as an additional marker of the field defect in these tumors.
MGMT is a DNA repair gene and plays a key role in protecting cells against the cytotoxic, mutagenic, and clastogenic effects of agents inducing O 6 -alkylguanine in DNA. Moreover, it is a major determinant of the resistance of cells to various alkylating cytostatic drugs, such as procarbazine, decarbazine, and temozolomide and chloroethylating agents, such as carmustine, nimustine, elmustine fotemustine, and others (53) . Although low frequency of MGMT hypermethylation in singly occurring endometrial and ovarian cancers was reported (24, 51, 52), a positive correlation was shown between the protein activity and the histologic grade and the International Federation of Gynaecology and Obstetrics stage of primary ovarian tumors (54) . Interestingly, MGMT activity was significantly higher in serous epithelial tumors compared with nonserous epithelial tumors (687 F 53 versus 479 F 45 fmol/mg, P = 0.010) defining, among this second group, a fraction of potentially chemosensitive ovarian carcinomas (about 5% of cases) characterized by very low MGMT activity.
In conclusion, our data suggest that synchronous primary endometrial and ovarian carcinomas show a high frequency of de novo hMLH1, CDKN2A, and MGMT methylation; in addition, they may comprise a set of gynaecologic malignancies with a specific sensitivity to alkylating chemotherapy. Prospective clinical trials are required to verify whether MGMT methylation with subsequent gene silencing may play a role in modulating the clinical response and prognosis in these patients and to test if the detection of hMLH1, CDKN2A, and MGMT hypermethylation may be useful in the risk assessment for these tumors.
